Zacks: Brokerages Expect Sanofi (SNY) Will Post Earnings of $0.69 Per Share
Wall Street brokerages expect Sanofi (NYSE:SNY) to post earnings of $0.69 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Sanofi’s earnings, with the lowest EPS estimate coming in at $0.67 and the highest estimate coming in at $0.71. Sanofi reported earnings of $0.67 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 3%. The firm is scheduled to report its next earnings results on Wednesday, February 14th.
According to Zacks, analysts expect that Sanofi will report full year earnings of $3.28 per share for the current year, with EPS estimates ranging from $3.18 to $3.42. For the next financial year, analysts anticipate that the business will report earnings of $3.41 per share, with EPS estimates ranging from $3.22 to $3.66. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Sanofi.
SNY has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. raised Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Finally, BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $53.50.
A number of institutional investors and hedge funds have recently modified their holdings of SNY. Bank of Nova Scotia Trust Co. bought a new stake in Sanofi during the 3rd quarter worth approximately $125,000. Parallel Advisors LLC increased its holdings in Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC increased its holdings in Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares in the last quarter. Eagle Ridge Investment Management bought a new stake in Sanofi during the 2nd quarter worth approximately $160,000. Finally, Bronfman E.L. Rothschild L.P. increased its holdings in Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares in the last quarter. 9.13% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/01/zacks-brokerages-expect-sanofi-sny-will-post-earnings-of-0-69-per-share.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.